Pharmacyclics Releases Data on Antrin Photoangioplasty
BARCELONA, Spain, Sept. 3 -- Pharmacyclics Inc. has reported results of Phase I clinical trials of photoangioplasty using injections of Antrin (motexafin lutetium). The company says the data showed the treatment to be safe, well tolerated and clinically active in patients with symptomatic peripheral arterial disease -- blockages of the arteries in the lower extremities. The findings were presented at the 21st Congress of the European Society of Cardiology.
The study was conducted at the Mid-America Heart Institute in Kansas City, Mo. and at Stanford University Medical Center. Fifty-one...Read full article
Related content from Photonics Media
Published: September 1999